Peripheral site ligand-oxime conjugates: A novel concept towards reactivation of nerve agent-inhibited human acetylcholinesterase

Bioorganic and Medicinal Chemistry

Volumn 19, Issue 1, 2011, Pages 588-594

  De Koning, M C ^a   Joosen, M J A ^a   Noort, D ^a   Van Zuylen, A ^a   Tromp, M C ^a  

^a TNO   (Netherlands)

Author keywords

Acetylcholinesterase; Nerve agent; Oxime; Peripheral site; Reactivation

Indexed keywords

1 (4 PYRIDINIUMALDOXIME) 2 (((2 CHLOROETHOXY) 2 ETHOXY)ETHOXY)ETHANE; 1 (4 PYRIDINIUMALDOXIME) 2 ((2 CHLOROETHOXY) 2 ETHOXY)ETHANE; 1 (4 PYRIDINIUMALDOXIME) 2 (2 CHLOROETHOXY)ETHANE; ACETYLCHOLINESTERASE; LIGAND; OXIME; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CONJUGATION; ENZYME REACTIVATION; EVALUATION; HUMAN; SYNTHESIS;

ACETYLCHOLINESTERASE; BLOOD-BRAIN BARRIER; CHEMICAL WARFARE AGENTS; CHOLINESTERASE INHIBITORS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; OXIMES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 78650720518     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.10.059     Document Type: Article

References (41)

1. J.L. Sussman, M. Harel, F. Frolow, C. Oefner, A. Goldman, L. Toker, and I. Silman Science 253 1991 872
2. P. Masson, P. Legrand, C.F. Bartels, M.-T. Froment, L.M. Schopger, and O. Lockridge Biochemistry 36 1997 2266
3. T. Szegletes, W.D. Mallender, P.J. Thomas, and T.L. Rosenberry Biochemistry 38 1999 122
4. D.M. Quinn Chem. Rev. 87 1987 955
5. T.C. Marrs Pharmacol. Therap. 58 1993 51
6. F. Worek, P. Eyer, N. Aurbek, L. Szinicz, and H. Thiermann Toxicol. Appl. Pharmacol. 219 2007 226
7. J. Bajgar, J. Fusek, K. Kuca, L. Bartosova, and D. Jun Mini-Rev. Med. Chem. 7 2007 461
8. C. Luo, M. Tong, N. Chilukuri, K. Brecht, D.M. Maxwell, and A. Saxena Biochemistry 46 2007 11771
9. P.M. Lundy, L. Raveh, and G. Amitai Toxicol. Rev. 25 2006 231
10. K. Sakurada, K. Matsubara, K. Shimizu, H. Shiono, Y. Seto, K. Tsuge, M. Yoshino, I. Sakai, H. Mukoyama, and T. Takatori Neurochem. Res. 28 2003 1401
11. H.P. Benschop, A.M. van Oosten, D.H.J.M. Platenburg, and C. van Hooidonk J. Med. Chem. 13 1970 1208
12. H.P. Benschop, G.R. van den Berg, C. Van Hooidonk, L.P.A. De Jong, and C.E. Kientz J. Med. Chem. 22 1979 1306
13. R.A. Kenley, R.A. Howd, C.W. Mosher, and J.S. Winterle J. Med. Chem. 24 1981 1124
14. R.A. Kenley, C.D. Bedford, O.D. Dailey, R.A. Howd, and A. Miller J. Med. Chem. 27 1984 1201
15. R.A. Kenley, C.D. Bedford, R.A. Howd, and S.E. Jackson Biochem. Pharm. 34 1985 3606
16. C.D. Bedford, R.A. Howd, O.D. Dailey, A. Miller, H.W. Nolen III, R.A. Kenley, J.R. Kern, and J.S. Winterle J. Med. Chem. 29 1986 2174
17. C.D. Bedford, M. Miura, J.C. Bottaro, R.A. Howd, and H.W. Nolen III J. Med. Chem. 29 1986 1689
18. F. Degorre, D. Kiffer, and F. Terrier J. Med. Chem. 31 1988 757
19. K. Kuca, D. Jun, and K. Musilek Mini-Rev. Med. Chem. 6 2006 269
20. H.C. Jeong, N.S. Kang, N.-J. Park, E.K. Yum, and Y.-S. Jung Bioorg. Med. Chem. Lett. 19 2009 1214
21. H. Ohta, T. Ohmori, S. Suzuki, H. Ikegaya, K. Sakurada, and T. Takatori Pharm. Res. 23 2006 2827
22. S. Okuno, K. Sakurada, H. Ohta, H. Ikegaya, Y. Kazui, T. Akutsu, T. Takatori, and K. Iwadate Toxicol. Appl. Pharmacol. 227 2008 8
23. Y.E. Kwon, J.Y. Park, K.T. No, J.H. Shin, S.K. Lee, J.S. Eun, J.H. Yang, T.Y. Shin, D.K. Kim, B.S. Chae, J.-Y. Leem, and K.H. Kim Bioorg. Med. Chem. 15 2007 6596
24. W.G. Lewis, L.G. Green, F. Grynszpan, Z. Radić, P.R. Carlier, P. Taylor, M.G. Finn, and K.B. Sharpless Angew. Chem. 41 2002 1053
25. R. Manetsch, A. Kransinski, Z. Radić, J. Raushel, P. Taylor, K.B. Sharpless, and H.C. Kolb J. Am. Chem. Soc. 126 2004 12809
26. G.L. Ellman, K.D. Courtney, V. Anders Jr., and R.M. Feather-Stone Biochem. Pharmacol. 7 1961 88
27. S. Ginsburg, and I.B. Wilson J. Am. Chem. Soc. 79 1957 481
28. All biological tests described in this manuscript were performed in triplicate.
29. The results of reactivation at other concentrations are depicted in Figure S3 in Supplementary data.
30. Interestingly, when sarin-inhibited electric eel AChE was used instead of human AChE, reactivation by HI-6 was poor, whereas the conjugates 1a-c performed comparably as with human AChE, thus dominating HI-6. Graphs of inhibition/reactivation experiments using electric eel AChE are given in Figure S4 in Supplementary data.
31. More reactivation experiments with varying inhibitors were carried out by Dr. F. Worek (IPT, Germany). The results of these experiments are given in the supporting information (Fig. S5). These results show the same trends (enhanced reactivation of the total construct compared to the parent compounds), but the percentage reactivation is generally somewhat lower. These differences can be attributed to the use of a slightly different method employing erythrocyte hAChE (ghosts).
32. Y. Ashani, Z. Radic, I. Tsigelny, D.C. Vellom, N.A. Pickering, D.M. Quinn, B.P. Doctor, and P. Taylor J. Biol. Chem. 270 1995 6370
33. T.L. Rosenberry, J.L. Johnson, B. Cusack, J.L. Thomas, S. Emani, and K.S. Venkatasubban Chem. Biol. Interact. 157-158 2005 181
34. R.J. Kitz, L.M. Braswell, and S. Ginsburg Mol. Pharmacol. 6 1969 108
35. G. Tomlinson, B. Mutus, and I. McLennan Mol. Pharamacol. 18 1980 33
36. L. Brochier, Y. Pontié, M. Willson, S. Estrada-Mondaca, J. Czaplicki, A. Klaébé, and D. Fournier J. Biol. Chem. 276 2001 18296
37. T.L. Rosenberry, L.K. Sonoda, S.E. Dekat, B. Cusack, and J.L. Johnson Chem. Biol. Interact. 175 2008 235
38. H.D. Crone J. Neurochem. 20 1973 225
39. L.W. Harris, W.C. Heyl, D.L. Stitcher, and C.A. Broomfield Biochem. Pharmacol. 27 1978 757
40. The inhibition curve of propidium iodide is given in Figure S1 in Supplementary data.
41. The idea for conjugation of a peripheral site ligand and a reactivating oxime as a dual site binding reactivator was recently mentioned in the literature. P. Taylor, Z. Kovarik, E. Reiner, and Z. Radić Toxicology 233 2007 70